Pharmacogenetic Testing Market Analysis

Therapeutic Area (Cardiology, Gastroenterology, Anesthesiology, Genomics, Endocrinology, Immunology & Hypersensitivity, Dermatology, Gynecology, Oncology, Neurology)

In terms of therapeutic area, the oncology segment in the pharmacogenetic testing market is anticipated to hold the highest CAGR of 20% by the end of 2036. The growth of this industry can be primarily driven by increasing focus and massive expenditure on cancer research. The global number of cancer cases has grown in the last few years and they are expected to double and triple by the end of 2050. Therefore, this would create a lucrative demand for effective and personalized cancer treatments. Cancer is the leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths, reported as of World Health Organization.

Distribution Channel (Hospital Pharmacy, Retail Pharmacies, Mail-Order Pharmacies, Direct-to-Customer Services)

Based on distribution channel, the hospital pharmacy segment is expected to hold 40% share of the global pharmacogenetic testing market during the time period between 2024-2036. Pharmacogenetic testing can aid in identifying patients who are unlikely to respond to certain medications or at risk of severe side effects leading to more targeted and effective plans. This translates to enhanced clinical outcomes, reduced hospital readmissions and lowered healthcare costs.

Our in-depth analysis of the global market includes the following segments:

Type	Whole Genome Sequencing Whole Exome Sequencing Array-Based Tests Single Gene Tests
Gene Type	CYP2C19 CYP2D6 CYP2C9 & VKORC1 CYP1A2 HLA-B1502 HLA-B5701 CYP2D OPRM1 ONCOTYPE DX & MAMMAPRINT DRD3 D4D4 SLC6A4 HTR2A/C TMPT
Drug Type	Prescription Drugs Nutraceuticals Recreational Drugs Herbal Supplements Vitamins Over-the-Counter Medications
Sample	Blood Saliva
Therapeutic Area	Cardiology Gastroenterology Anesthesiology Genomics Endocrinology Immunology & Hypersensitivity Dermatology Gynecology Oncology Neurology
Application	Clinical Practice Drug Development Drug Regulation
End User	Healthcare Providers Pharmaceutical & Biotechnology Companies Research Centres and Academic Institutes
Distribution Channel	Hospital Pharmacy Retail Pharmacies Mail-Order Pharmacies Direct-to-Customer Services

Frequently Asked Questions (FAQ)

The growing demand for personalized medicines and growing integration EHR are some of the major factors anticipated to drive the growth of the pharmacogenetic testing market.

The market is anticipated to attain a CAGR of ~9% over the forecast period, i.e., 2024-2036.

The major players in the market are of Thermo Fisher Scientific Inc., Dynamic DNA Laboratories, Sonic Healthcare, QIAGEN, Eurofins Scientific, 23andMe, Inc, and others.

The hospital pharmacy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Pharmacogenetic Testing Market Analysis